Tracer library / [212Pb]Pb-212-TCMC-trastuzumab
[212Pb]Pb-212-TCMC-trastuzumab
Also written as Pb-212-TCMC-trastuzumab
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 2
What it is
- Compound class
- Radiolabeled monoclonal antibody (TCMC-conjugated anti-HER2 antibody trastuzumab, alpha-particle immunoconjugate)
- Target / mechanism
- HER2-targeting via trastuzumab antibody delivering alpha-emitting 212Pb PMID 24229395
- Clinical application
- Intraperitoneal targeted alpha-particle radioimmunotherapy for HER-2-expressing peritoneal carcinomatosis (e.g., ovarian cancer) PMID 25157044
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 92.2% to 99.6% | 90.2% to 100% | TCMC-trastuzumab Goodwin Biotechnology, Inc. | 26230702 2015 Pharmaceuticals (Basel) TCMC-trastuzumab was then labeled with 212Pb as previously described - Radiolabelling efficiency of the cGMP TCMC-trastuzumab with 212Pb ranged from 92.2% to 99.6% |
| Manual synthesis | — | SPE | — | 82.1% 83% | TCMC-trastuzumab Goodwin Biotechnology, Inc. | 26230702 2015 Pharmaceuticals (Basel) The 203Pb solution was neutralized and the cGMP TCMC-trastuzumab (100 µg) added, vortexed and incubated at 37 °C for 1 h |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.2014 · J Nucl Med · Clinical study · Phase I
- Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.2014 · Cancer Biother Radiopharm · Clinical study
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Goodwin Biotechnology
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [212Pb]Pb-212-TCMC-trastuzumab, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 26230702: '1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane-trastuzumab (212Pb-TCMC-trastuzumab)'. Stage set/updated at stage 23 from PMID 25157044: 'Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.'. | Stage 30 (2026-09-18): Stage was 'Phase I clinical trial (first-in-human)'; normalised to 'Clinical research', original wording kept here.